vs

Side-by-side financial comparison of Ponce Financial Group, Inc. (PDLB) and Theravance Biopharma, Inc. (TBPH). Click either name above to swap in a different company.

Theravance Biopharma, Inc. is the larger business by last-quarter revenue ($45.9M vs $31.4M, roughly 1.5× Ponce Financial Group, Inc.). Theravance Biopharma, Inc. runs the higher net margin — 133.0% vs 36.3%, a 96.7% gap on every dollar of revenue. On growth, Theravance Biopharma, Inc. posted the faster year-over-year revenue change (144.7% vs 37.6%). Over the past eight quarters, Theravance Biopharma, Inc.'s revenue compounded faster (77.9% CAGR vs 23.7%).

Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.

Theravance Biopharma, Inc. is a global biopharmaceutical enterprise focused on researching, developing and commercializing innovative medicines for patients with serious, unmet medical needs, primarily targeting respiratory and infectious disease segments. It operates core markets across North America and Europe, partnering with global healthcare stakeholders to advance its therapy pipeline and deliver effective, accessible treatment options to underserved patient groups.

PDLB vs TBPH — Head-to-Head

Bigger by revenue
TBPH
TBPH
1.5× larger
TBPH
$45.9M
$31.4M
PDLB
Growing faster (revenue YoY)
TBPH
TBPH
+107.1% gap
TBPH
144.7%
37.6%
PDLB
Higher net margin
TBPH
TBPH
96.7% more per $
TBPH
133.0%
36.3%
PDLB
Faster 2-yr revenue CAGR
TBPH
TBPH
Annualised
TBPH
77.9%
23.7%
PDLB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PDLB
PDLB
TBPH
TBPH
Revenue
$31.4M
$45.9M
Net Profit
$10.1M
$61.0M
Gross Margin
Operating Margin
43.6%
43.6%
Net Margin
36.3%
133.0%
Revenue YoY
37.6%
144.7%
Net Profit YoY
245.6%
493.0%
EPS (diluted)
$0.43
$1.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PDLB
PDLB
TBPH
TBPH
Q4 25
$31.4M
$45.9M
Q3 25
$26.7M
$20.0M
Q2 25
$26.5M
$26.2M
Q1 25
$24.6M
$15.4M
Q4 24
$22.8M
$18.8M
Q3 24
$20.2M
$16.9M
Q2 24
$20.2M
$14.3M
Q1 24
$20.5M
$14.5M
Net Profit
PDLB
PDLB
TBPH
TBPH
Q4 25
$10.1M
$61.0M
Q3 25
$6.5M
$3.6M
Q2 25
$6.1M
$54.8M
Q1 25
$6.0M
$-13.6M
Q4 24
$2.9M
$-15.5M
Q3 24
$2.4M
$-12.7M
Q2 24
$3.2M
$-16.5M
Q1 24
$2.4M
$-11.7M
Operating Margin
PDLB
PDLB
TBPH
TBPH
Q4 25
43.6%
43.6%
Q3 25
32.8%
-32.3%
Q2 25
30.2%
-10.4%
Q1 25
32.5%
-93.8%
Q4 24
19.6%
-49.1%
Q3 24
15.2%
-64.2%
Q2 24
21.8%
-110.2%
Q1 24
18.3%
-77.3%
Net Margin
PDLB
PDLB
TBPH
TBPH
Q4 25
36.3%
133.0%
Q3 25
24.3%
18.1%
Q2 25
23.0%
209.3%
Q1 25
24.2%
-88.2%
Q4 24
14.1%
-82.8%
Q3 24
12.1%
-75.3%
Q2 24
15.8%
-115.9%
Q1 24
11.8%
-80.4%
EPS (diluted)
PDLB
PDLB
TBPH
TBPH
Q4 25
$0.43
$1.18
Q3 25
$0.27
$0.07
Q2 25
$0.25
$1.08
Q1 25
$0.25
$-0.27
Q4 24
$0.11
$-0.31
Q3 24
$0.10
$-0.26
Q2 24
$0.14
$-0.34
Q1 24
$0.11
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PDLB
PDLB
TBPH
TBPH
Cash + ST InvestmentsLiquidity on hand
$126.2M
$167.8M
Total DebtLower is stronger
$596.1M
Stockholders' EquityBook value
$541.5M
$296.7M
Total Assets
$3.2B
$485.6M
Debt / EquityLower = less leverage
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PDLB
PDLB
TBPH
TBPH
Q4 25
$126.2M
$167.8M
Q3 25
$146.6M
$174.8M
Q2 25
$126.6M
$281.9M
Q1 25
$129.9M
$110.6M
Q4 24
$139.8M
$37.8M
Q3 24
$155.8M
$23.4M
Q2 24
$103.2M
$46.3M
Q1 24
$134.7M
$53.8M
Total Debt
PDLB
PDLB
TBPH
TBPH
Q4 25
$596.1M
Q3 25
$521.1M
Q2 25
$536.1M
Q1 25
$521.1M
Q4 24
$596.1M
Q3 24
$580.4M
Q2 24
$680.4M
Q1 24
$680.4M
Stockholders' Equity
PDLB
PDLB
TBPH
TBPH
Q4 25
$541.5M
$296.7M
Q3 25
$529.8M
$232.7M
Q2 25
$521.1M
$224.8M
Q1 25
$513.9M
$166.0M
Q4 24
$505.5M
$175.5M
Q3 24
$504.6M
$185.7M
Q2 24
$497.7M
$193.7M
Q1 24
$493.7M
$204.9M
Total Assets
PDLB
PDLB
TBPH
TBPH
Q4 25
$3.2B
$485.6M
Q3 25
$3.2B
$415.5M
Q2 25
$3.2B
$426.0M
Q1 25
$3.1B
$343.6M
Q4 24
$3.0B
$354.2M
Q3 24
$3.0B
$356.1M
Q2 24
$2.8B
$362.0M
Q1 24
$2.8B
$371.3M
Debt / Equity
PDLB
PDLB
TBPH
TBPH
Q4 25
1.10×
Q3 25
0.98×
Q2 25
1.03×
Q1 25
1.01×
Q4 24
1.18×
Q3 24
1.15×
Q2 24
1.37×
Q1 24
1.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PDLB
PDLB
TBPH
TBPH
Operating Cash FlowLast quarter
$55.6M
$-6.1M
Free Cash FlowOCF − Capex
$54.6M
FCF MarginFCF / Revenue
173.9%
Capex IntensityCapex / Revenue
3.1%
Cash ConversionOCF / Net Profit
5.48×
-0.10×
TTM Free Cash FlowTrailing 4 quarters
$74.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PDLB
PDLB
TBPH
TBPH
Q4 25
$55.6M
$-6.1M
Q3 25
$1.4M
$-6.5M
Q2 25
$6.2M
$208.1M
Q1 25
$13.1M
$43.0M
Q4 24
$7.2M
$-902.0K
Q3 24
$-14.6M
$-5.2M
Q2 24
$-2.6M
$-4.4M
Q1 24
$1.5M
$-1.0M
Free Cash Flow
PDLB
PDLB
TBPH
TBPH
Q4 25
$54.6M
Q3 25
$786.0K
Q2 25
$5.9M
Q1 25
$12.9M
Q4 24
$4.5M
$-1.1M
Q3 24
$-15.0M
$-5.2M
Q2 24
$-2.6M
$-4.5M
Q1 24
$-315.0K
$-1.1M
FCF Margin
PDLB
PDLB
TBPH
TBPH
Q4 25
173.9%
Q3 25
2.9%
Q2 25
22.4%
Q1 25
52.6%
Q4 24
19.7%
-5.8%
Q3 24
-74.1%
-30.9%
Q2 24
-13.0%
-31.2%
Q1 24
-1.5%
-7.7%
Capex Intensity
PDLB
PDLB
TBPH
TBPH
Q4 25
3.1%
Q3 25
2.3%
0.0%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
11.9%
1.0%
Q3 24
2.0%
0.1%
Q2 24
0.3%
0.3%
Q1 24
8.7%
0.6%
Cash Conversion
PDLB
PDLB
TBPH
TBPH
Q4 25
5.48×
-0.10×
Q3 25
0.21×
-1.80×
Q2 25
1.01×
3.79×
Q1 25
2.20×
Q4 24
2.46×
Q3 24
-5.99×
Q2 24
-0.80×
Q1 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons